Pine River Capital Management’s Sciclone Pharmaceuticals SCLN Stock Holding History
Bought
Maintained
Sold
Other funds holding SCLN
Pine River Capital Management's SCLN Position: Q2 2017 in Review
Pine River Capital Management sold out of Sciclone Pharmaceuticals (SCLN) in Q2 2017, closing a stake of 405,985 shares — an estimated $3.98M sold.
Pine River Capital Management first reported a position in SCLN in Q4 2016 and held it in 2 quarters. The position peaked at $3.98M in Q1 2017. 142 funds tracked by Wall St. Rank hold SCLN as of Q2 2017.
- Pine River Capital Management reported no remaining Sciclone Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
- Pine River Capital Management sold 405,985 Sciclone Pharmaceuticals shares in Q2 2017, an estimated $3.98M.
- Pine River Capital Management first reported a position in Sciclone Pharmaceuticals in Q4 2016 and held it in 2 quarters.
- Pine River Capital Management's Sciclone Pharmaceuticals position peaked at $3.98M in Q1 2017.
- 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals as of Q2 2017.
Based on Pine River Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.